Synapse - Christopher Azzoli

Results (12)

Phase II study of docetaxel and vinorelbine as adjuvant chemotherapy for resected non-small cell lung cancers

Journal Article

Chaft, J. E.; Rekhtman, N.; Sima, C. S.; Rusch, V.; Kris, M. G.; Zakowski, M.; Azzoli, C. G.
Cancer Chemotherapy and Pharmacology (2013)

Fulltext@MSK | Save

Distinct clinical course of EGFR-mutant resected lung cancers: Results of testing of 1118 surgical specimens and effects of adjuvant gefitinib and erlotinib

Journal Article

D'Angelo, S. P.; Janjigian, Y. Y.; Ahye, N.; Riely, G. J.; Chaft, J. E.; Sima, C. S.; Shen, R.; Zheng, J.; Dycoco, J.; Kris, M. G.; more...
Journal of Thoracic Oncology (2012)

Fulltext@MSK | Save

Molecular characteristics predict clinical outcomes: Prospective trial correlating response to the EGFR tyrosine kinase inhibitor gefitinib with the presence of sensitizing mutations in the tyrosine binding domain of the EGFR gene

Journal Article

Rizvi, N. A.; Rusch, V.; Pao, W.; Chaft, J. E.; Ladanyi, M.; Miller, V. A.; Krug, L. M.; Azzoli, C. G.; Bains, M.; Downey, R.; more...
Clinical Cancer Research (2011)

Fulltext@MSK | Save

Impact on disease-free survival of adjuvant erlotinib or gefitinib in patients with resected lung adenocarcinomas that harbor EGFR mutations

Journal Article

Janjigian, Y. Y.; Park, B. J.; Zakowski, M. F.; Ladanyi, M.; Pao, W.; D'Angelo, S. P.; Kris, M. G.; Shen, R.; Zheng, J.; Azzoli, C. G.
Journal of Thoracic Oncology (2011)

Fulltext@MSK | Save

Reflex testing of resected stage i through III lung adenocarcinomas for EGFR and KRAS mutation: Report on initial experience and clinical utility at a single center